Testosterone gel vs injections: what actually differs?

Both routes can deliver replacement testosterone. The differences that matter are practical, measurable, and specific to the formulation.

Scientist looks through a microscope in a laboratory. Photo: Navy Medicine / Unsplash.
Written by the TrunkMD editorial team
Fact checked
Updated
  1. Updated
  2. Updated
  3. Updated
  4. Published

Testosterone gel and injections can both raise testosterone in men with confirmed deficiency. Gel requires regular skin application and precautions against transfer to others. Injections avoid skin transfer but involve needles, formulation-specific peaks and troughs, and often a greater tendency to raise hematocrit. Neither route reliably improves every symptom or preserves sperm production. Selection depends on the product, monitoring and individual circumstances.123

Key points

  • Gel concentration, application site and blood-test timing are product-specific.2
  • Comparative erythrocytosis evidence favors gels over some injections, but much of it is observational.3
  • A long-acting clinic injection has a different risk and convenience profile from a shorter-acting vial.45

Is one route more effective at treating low testosterone?

Neither route is universally more effective. A formulation can deliver an appropriate blood concentration yet fail to improve a symptom that has another cause. Conversely, a man may respond well to either gel or an injection when the diagnosis is sound and exposure is appropriately adjusted. Guidelines recommend choosing formulations around pharmacology, burden, patient preference and cost. 1

A useful comparison holds the treatment goal constant. If the goal is improved sexual desire, compare that response along with tolerability, rather than comparing the highest number each product can produce. Blood samples taken at different times after treatment are also not fair measures of effectiveness. The broader explanation of what replacement therapy treats separates achieving exposure from achieving a clinical benefit.

Why do levels fluctuate differently?

Gel is absorbed through the skin with repeated daily application. Shorter-acting oil-based injections form a depot that releases testosterone over time. The concentration can rise after an injection and decline before the next one, with the shape depending on the product and prescribed regimen. Gels generally produce less fluctuation than some intramuscular cypionate or enanthate regimens, but absorption can still vary. 1

An injection is therefore not automatically more stable or less stable than every gel. Xyosted is a subcutaneous enanthate autoinjector with its own pharmacokinetics and trough-based monitoring. Aveed is long-acting intramuscular undecanoate, with different administration and observation requirements. Lumping these together conceals clinically useful differences. 4 5

If symptoms appear to track the interval between administrations, record their timing and bring it to the prescriber. That pattern can inform assessment, but symptoms alone cannot establish the peak or trough or justify independently changing a regimen.

What changes in everyday use?

The main daily tradeoff is between a skin routine and an injection routine. Both require planning. One may fit a person's work, travel and household arrangements better, but neither is maintenance-free.

Practical differences to discuss before choosing a formulation
IssueGelInjection
RoutineRegular application to the specified skin sites. 2Administration schedule, training and supplies depend on product. 1
Contact with othersPrevent contact with unwashed or uncovered treated skin. 2No testosterone-coated skin site after a depot injection. 1
AdjustmentPrescriber can change later applications; products are not interchangeable pump for pump. 2Future injections can change, but an existing depot keeps releasing medicine. 1
Procedure burdenNo injection, but possible application-site irritation. 2Needles and possible site reactions; some products require clinic visits. 4 5
Blood-test meaningDepends on the exact gel and time relative to application. 2Depends on the formulation and position within the injection interval. 1 4

The table compares responsibilities rather than declaring a winner. A household with frequent close contact may find transfer precautions difficult. Someone with a strong needle aversion may find a daily application easier to sustain. These preferences become medically relevant when they affect consistent use.

A pen lies across an open paper calendar beside a small plant. Photo: Renáta-Adrienn / Unsplash.

How serious is testosterone transfer from gel?

Secondary exposure is a real product-specific hazard, and AndroGel 1.62% retains a boxed warning about it. Testosterone remaining on treated skin can expose another person, with virilization reported in children. Avoiding transfer is part of using the medicine correctly, not an optional hygiene preference. 2

The label directs handwashing after application, covering the application area after drying and washing the site before anticipated skin contact. Application sites and timing around bathing depend on the actual product. Instructions for one gel strength should not be copied to another strength or a compounded cream. 2

A useful pretreatment discussion considers childcare, intimate contact, shared routines and whether the required steps are realistic. If unexpected signs of androgen exposure appear in a household contact, seek medical advice promptly. Switching routes may solve a transfer problem, but it does not remove systemic risks such as elevated hematocrit or reduced sperm production.

Are injections more likely to raise hematocrit?

Some injection regimens appear more likely to raise hematocrit than gels. A retrospective comparison followed 47 gel users, 57 injection users and 74 pellet users. Using a hematocrit threshold above 50%, erythrocytosis occurred in 12.8%, 66.7% and 35.1%, respectively. The injection group was younger and had higher baseline blood counts and different testosterone exposure. 3

Those figures are not personalized risk forecasts. They came from one clinical cohort, the groups were not randomized, and a threshold above 50% differs from a guideline action threshold of 54%. The study supports discussing formulation when hematocrit rises; it cannot prove that every injection carries the same risk or that gel eliminates it. 1 3

The hematocrit monitoring guide explains why the trend, starting value, sleep apnea, smoking and the treatment regimen all affect interpretation. Changing routes is one possible clinical response, alongside investigating other contributors.

Laboratory sample tubes with colored caps stand in a yellow rack. Photo: Daniel Sone / National Cancer Institute / Unsplash.

When should blood tests be taken?

Timing must follow the exact product and the question being asked. For intramuscular cypionate or enanthate, the Endocrine Society describes mid-interval sampling. Xyosted uses trough testing. AndroGel 1.62% uses a pre-dose morning sample for titration. Generic advice to test a fixed number of hours after every gel can therefore conflict with a specific label. 1 2 4

Write down the product, the time of the last administration and the blood-draw time. A result without that context may create an apparent treatment failure or an apparent excess that reflects sampling rather than a genuine change. Diagnostic morning testing before therapy answers a different question from monitoring an administered drug.

The monitoring schedule also includes clinical response, blood pressure and hematocrit. Measuring testosterone more often does not compensate for omitting those checks. Nor does a good testosterone result show whether sperm production has been maintained.

What should guide a switch from one route to the other?

A switch is most informative when it addresses a defined problem: unacceptable skin precautions, inconsistent absorption, injection intolerance, troublesome fluctuations, rising hematocrit or an unaffordable continuing cost. The prescriber can then assess whether the new route actually improves that problem. 1

Neither route has a blanket cardiovascular exemption. FDA required blood-pressure warnings across testosterone products after its 2025 review. Aveed separately retains a boxed warning for pulmonary oil microembolism and anaphylaxis, and requires observation after administration. Removing cardiovascular boxed-warning language did not remove that product-specific warning. 5 6

The evidence-grounded comparison is therefore between two complete treatment plans. Compare the household routine, sampling plan, follow-up, supply costs and response target together. That produces a more useful decision than treating a gel or a syringe as inherently stronger, cleaner or safer.

Common questions

Can gel work if injections did not improve fatigue?

It may provide a different exposure pattern or improve tolerability, but a route change does not establish that fatigue is testosterone-related. Persistent symptoms despite appropriate levels need a review of the original diagnosis and other causes.1

Are injection and gel doses directly equivalent?

No. The amount placed on skin and the amount injected cannot be compared directly because absorption and release differ. Conversion requires a prescribed product-specific plan and follow-up testing.12

Does gel preserve fertility better?

A topical route does not remove the suppressive effect of external testosterone on reproductive signaling. Men planning fertility need counseling before treatment rather than assuming that a less invasive route protects sperm production.1

References

  1. 1.Bhasin S, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. JCEM. 2018.
  2. 2.ASCEND Therapeutics. AndroGel 1.62% prescribing information. DailyMed, revised October 2025.
  3. 3.Pastuszak AW, et al. Comparison of the Effects of Testosterone Gels, Injections, and Pellets on Serum Hormones, Erythrocytosis, Lipids, and Prostate-Specific Antigen. Sexual Medicine. 2015.
  4. 4.Antares Pharma. Xyosted prescribing information. DailyMed.
  5. 5.Endo USA. Aveed prescribing information. DailyMed, effective July 15, 2025.
  6. 6.FDA. FDA issues class-wide labeling changes for testosterone products. February 28, 2025.

This article is for general education, not medical advice, diagnosis or a treatment recommendation. A licensed clinician can interpret the evidence in the context of your symptoms, tests, medicines and fertility plans.